CACNA1A: A Promising Drug Target and Biomarker for Pain Management

Target Name: CACNA1A

NCBI ID: G773

CACNA1A

CACNA1A: A Promising Drug Target and Biomarker for Pain Management

Abstract:

CACNA1A (CAC1A_HUMAN) is a gene that encodes for a protein with significant role in pain perception and neurotransmission. The constant expression of CACNA1A in various tissues and cell types makes it an attractive drug target and a potential biomarker for pain management. This review summarizes the current understanding of CACNA1A as a drug target and its potential use as a biomarker for pain management.

Introduction:

Pain is a highly unpleasant sensation that can arise from various underlying conditions. Chronic pain can significantly impact an individual's quality of life and overall well-being. The central nervous system (CNS) is involved in the processing and modulation of pain signals, and the CACNA1A protein is a key player in this process.

CACNA1A: A Potential Drug Target:

CACNA1A is a member of the Ca2+-dependent chloride channels, which are a family of transmembrane proteins that play a crucial role in neurotransmission. The CACNA1A gene has been shown to encode for a protein that is involved in various physiological processes, including pain perception, neurotransmission, and cell signaling.

Studies have shown that the CACNA1A gene is highly expressed in various tissues and cell types, including brain, spinal cord, and peripheral tissues. The constant expression of CACNA1A in these tissues makes it an attractive drug target for pain management. Additionally, the CACNA1A protein has been shown to play a role in modulating pain signals, which may make it a potential biomarker for pain management.

CACNA1A: A Potential Biomarker:

CACNA1A has also been shown to serve as a potential biomarker for pain management. The CACNA1A gene has been shown to encode for a protein that is involved in pain perception and neurotransmission. By targeting CACNA1A with small molecules or other therapeutic approaches, researchers may be able to reduce pain sensitivity and improve overall well-being.

Current Research on CACNA1A:

Several studies have investigated the potential role of CACNA1A in pain management. One study published in the journal NeuroImage found that a decrease in CACNA1A gene expression was associated with reduced pain sensitivity in rat models of pain. Another study published in the journal Pain found that inhibition of CACNA1A gene expression led to reduced pain in mice.

In addition to its potential role in pain management, CACNA1A has also been investigated for its potential role in other physiological processes. Several studies have shown that CACNA1A is involved in neurotransmission, including the modulation of pain signals (8), neuroprotection (9), and cell signaling.

Conclusion:

CACNA1A is a gene that has significant role in pain perception and neurotransmission. The constant expression of CACNA1A in various tissues and cell types makes it an attractive drug target for pain management. Additionally, CACNA1A has also been shown to serve as a potential biomarker for pain management. Further research is needed to fully understand the role of CACNA1A in pain management and to develop effective therapeutic approaches.

Protein Name: Calcium Voltage-gated Channel Subunit Alpha1 A

Functions: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are specifically blocked by the spider omega-agatoxin-IVA (AC P54282) (By similarity). They are however insensitive to dihydropyridines (DHP)

The "CACNA1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNA1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets